Additional recurrent mutations and/or epigenetic changes of genes involved in PI3K/AKT signaling, cell cycle control (RB1, CDKN2A, and TP53), and other pathways were found in cutaneous melanoma; these regulate the course of the disease and could become targets of new therapeutic approaches [33,34]. This evidence concerns the gene TP53 and cutaneous melanoma.